Genzyme Begins Major Expansion of Boston Manufacturin...(00 square feetof new office and manufact...)

Genzyme began construction of Allston Landing in the early 1990s, and the facility was initially intended to produce one product -- Cerezyme(R) (imiglucerase for injection) for Type 1 Gaucher disease. While the physical size and layout of the facility have remained largely unchanged, Genzyme is now producing five products at the facility. Three are manufactured there: Cerezyme; Fabrazyme(R) (agalsidase beta) for Fabry disease; and Myozyme(R) (alglucosidase alfa) for Pompe disease. Genzyme also performs the filling and packaging for two products manufactured at other sites: Aldurazyme(R) (laronidase) for MPS I disease and Thyrogen(R) (thyrotropin alfa for injection), used in the screening of patients who have had thyroid cancer. Genzyme last expanded the site in 2004.

The Allston Landing facility is a highly visible landmark located between Storrow Drive and the Massachusetts Turnpike. The design and brick facade of the existing building establish a strong visual link to nearby universities. The expanded site has been designed to reflect a significantly more modern and transparent image, in keeping with Genzyme's continuing desire to embrace these qualities in its corporate culture. The design also will serve to symbolically open up the facility to the surrounding community.

The Allston expansion will incorporate environmentally responsible building practices similar to those used in Genzyme Center-the company's Cambridge headquarters-and its new Science Center in Framingham. Genzyme intends to seek certification for the expansion under the U.S. Green Building Council's LEED(R) (Leadership in Energy and Environmental Design) Green Building Rating System(TM).

The expanded facility will permanently house wo
'/>"/>